目的·探索血管抑制蛋白2(vasohibin-2,VASH2)在三阴性乳腺癌(triple-negative breast cancer,TNBC)中的表达及VASH2通过调控基因表达和可变剪接在TNBC发生发展中的作用机制。方法·通过基因型-组织表达数据库(GenotypeTissue E...目的·探索血管抑制蛋白2(vasohibin-2,VASH2)在三阴性乳腺癌(triple-negative breast cancer,TNBC)中的表达及VASH2通过调控基因表达和可变剪接在TNBC发生发展中的作用机制。方法·通过基因型-组织表达数据库(GenotypeTissue Expression,GTEx)联合癌症基因组图谱数据库(The Cancer Genome Atlas,TCGA)比较VASH2在TNBC中与正常乳腺组织中的表达差异,并分析VASH2在TNBC中的甲基化水平。在TNBC细胞系MDA-MB-231中对VASH2过表达,并进行转录组测序,分析受VASH2所调控的差异表达基因及可变剪接基因。结果·VASH2在TNBC组织中与正常组织及其他乳腺癌分型比较表达水平显著提高。VASH2基因的低甲基化可能是VASH2在TNBC中表达上调的原因之一。VASH2过表达后引起81个基因显著差异表达,其中上调的基因23个,下调的基因58个。VASH2过表达后可变剪接水平发生显著变化的基因主要富集在细胞周期、p53信号通路上。结论·VASH2可能通过调控TNBC中基因可变剪接促进其发生和发展。展开更多
The studies of SCAIF I(an unknown protein) by HPLC and ESIMS was reported in this paper. The SCAIF I is a kind of antiangiogenesis extracted from shark cartilage. The extracted protein was purified by HPLC and then st...The studies of SCAIF I(an unknown protein) by HPLC and ESIMS was reported in this paper. The SCAIF I is a kind of antiangiogenesis extracted from shark cartilage. The extracted protein was purified by HPLC and then studied by ESIMS. The molecule weight of the SCAIF I protein was confirmed to be 15 601 in the first time. Peptide map of the unknown protein was obtained by HPLC ESIMS with a trypsin digestion and possible partial sequences were deduced with the online CID technique. With partial sequence information the homologous proteins are searched with protein database. The homology of SCAIF I summarized in this work is useful in further studies of this unknown protein.展开更多
目的研究慢性心力衰竭(CHF)患者血浆血管抑制因子2(VS2)水平及其潜在临床意义。方法参照Framingham临床心力衰竭的诊断标准,入选216例CHF患者为研究组,其中无或轻度CHF症状93例,中重度CHF症状123例;缺血性心脏病99例,非缺血性心脏病117...目的研究慢性心力衰竭(CHF)患者血浆血管抑制因子2(VS2)水平及其潜在临床意义。方法参照Framingham临床心力衰竭的诊断标准,入选216例CHF患者为研究组,其中无或轻度CHF症状93例,中重度CHF症状123例;缺血性心脏病99例,非缺血性心脏病117例。选择同期171例体检健康者为对照组。用ELISA法测定血浆VS2水平。结果研究组血浆VS2水平显著低于对照组[0.805(0.547,1.187)μg/L vs 0.983(0.510,1.783)μg/L,P=0.011]。无或轻度CHF症状与中重度CHF症状者VS2水平比较无显著差异(P=0.908),缺血性心脏病与非缺血性心脏病患者VS2水平比较无显著差异(P=0.409)。123例中重度CHF症状患者VS2水平与心率呈负相关(r=-0.198,P=0.028)。结论 CHF患者血浆VS2水平降低,VS2与心力衰竭程度无关。展开更多
文摘目的·探索血管抑制蛋白2(vasohibin-2,VASH2)在三阴性乳腺癌(triple-negative breast cancer,TNBC)中的表达及VASH2通过调控基因表达和可变剪接在TNBC发生发展中的作用机制。方法·通过基因型-组织表达数据库(GenotypeTissue Expression,GTEx)联合癌症基因组图谱数据库(The Cancer Genome Atlas,TCGA)比较VASH2在TNBC中与正常乳腺组织中的表达差异,并分析VASH2在TNBC中的甲基化水平。在TNBC细胞系MDA-MB-231中对VASH2过表达,并进行转录组测序,分析受VASH2所调控的差异表达基因及可变剪接基因。结果·VASH2在TNBC组织中与正常组织及其他乳腺癌分型比较表达水平显著提高。VASH2基因的低甲基化可能是VASH2在TNBC中表达上调的原因之一。VASH2过表达后引起81个基因显著差异表达,其中上调的基因23个,下调的基因58个。VASH2过表达后可变剪接水平发生显著变化的基因主要富集在细胞周期、p53信号通路上。结论·VASH2可能通过调控TNBC中基因可变剪接促进其发生和发展。
文摘The studies of SCAIF I(an unknown protein) by HPLC and ESIMS was reported in this paper. The SCAIF I is a kind of antiangiogenesis extracted from shark cartilage. The extracted protein was purified by HPLC and then studied by ESIMS. The molecule weight of the SCAIF I protein was confirmed to be 15 601 in the first time. Peptide map of the unknown protein was obtained by HPLC ESIMS with a trypsin digestion and possible partial sequences were deduced with the online CID technique. With partial sequence information the homologous proteins are searched with protein database. The homology of SCAIF I summarized in this work is useful in further studies of this unknown protein.
文摘目的研究慢性心力衰竭(CHF)患者血浆血管抑制因子2(VS2)水平及其潜在临床意义。方法参照Framingham临床心力衰竭的诊断标准,入选216例CHF患者为研究组,其中无或轻度CHF症状93例,中重度CHF症状123例;缺血性心脏病99例,非缺血性心脏病117例。选择同期171例体检健康者为对照组。用ELISA法测定血浆VS2水平。结果研究组血浆VS2水平显著低于对照组[0.805(0.547,1.187)μg/L vs 0.983(0.510,1.783)μg/L,P=0.011]。无或轻度CHF症状与中重度CHF症状者VS2水平比较无显著差异(P=0.908),缺血性心脏病与非缺血性心脏病患者VS2水平比较无显著差异(P=0.409)。123例中重度CHF症状患者VS2水平与心率呈负相关(r=-0.198,P=0.028)。结论 CHF患者血浆VS2水平降低,VS2与心力衰竭程度无关。
